Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature

The third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) established a new standard for EGFR mutation positive non-small cell lung cancer (NSCLC) treatment. Brain metastases (BMS) are common in NSCLCs with poor prognosis, and patients with BMS who carry uncommon...

Descripción completa

Detalles Bibliográficos
Autor principal: Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474834/
https://www.ncbi.nlm.nih.gov/pubmed/36119883
http://dx.doi.org/10.1016/j.heliyon.2022.e10407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474834/
https://www.ncbi.nlm.nih.gov/pubmed/36119883
http://dx.doi.org/10.1016/j.heliyon.2022.e10407

Ejemplares similares